S-Patch Ex, Wearable ECG Patch, Cleared by US FDA

Lightest weighing ECG patch in the market designed for comfort and ease of use Embedded with Samsung’s Next-Generation bio-processor proven to capture world’s most accurate ECG waveforms

SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ — Wellysis, a spin-off company from Samsung SDS, has received clearance from the U.S. Food and Drug Administration (FDA) on August 30, 2023, to market its wearable electrocardiography (ECG) patch, S-Patch Ex, in the U.S. The product, which received EU’s CE mark in May 2021, is currently being exported to 14 countries worldwide, including UK, Spain, Italy, Greece, Poland, Australia, Thailand, India, and Korea.

The S-Patch Ex is an ECG and heart rate recording device for use by healthcare professionals and patients both at home and in clinical settings. The product is embedded with Samsung Electronics’ Next-Generation bio-processor which ensures the device captures accurate ECG waveforms. The product is expected to be officially launched in the U.S. market in September by establishing partnerships with service and platform providers.

With the latest technologies on board, the performance and features of the product are unparallel to those of key players in the wearable patch market. Weighing just 9g, S-Patch Ex offers the market’s lightest weight, continuous test duration, and integrates with mobile phones, tablets, and watches, as well as compatible with any commercially available electrodes and batteries. Furthermore, the product is reusable and equipped with waterproof and dustproof features, boasting an IP55 rating, ensuring durability in various conditions.

“S-Patch Ex is designed with patience-centric for approach to ensure their comfort and ease of use in most daily activities. It also provides the most accurate information to the physicians. We are excited to introduce its outstanding features to the US market base with the FDA clearance in the U.S.,” said Young Juhn, CEO and Founder of Wellysis.

S-Patch Ex is used predominantly on patients with symptoms such as palpitations.  Most recently, the device is also used in research with long COVID patients for ECG monitoring in institutions such as Stanford University in the U.S. and Liverpool Hospital in Australia.

About Wellysis

Wellysis is a South Korean startup founded in 2019 as a spin-off from Samsung SDS’s Digital Health division by a team of experts with extensive experience in the healthcare field. The company has attracted investment from major pharmaceutical companies and investors, with a total of 12 million USD up to date. In just five years since its establishment, the company has successfully expanded its business to overseas markets, with over 790 hospitals and clinics using the product worldwide.

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.